DE69007744D1 - Verwendung von Interleukin 2 zur Behandlung von Leukämien. - Google Patents

Verwendung von Interleukin 2 zur Behandlung von Leukämien.

Info

Publication number
DE69007744D1
DE69007744D1 DE90402900T DE69007744T DE69007744D1 DE 69007744 D1 DE69007744 D1 DE 69007744D1 DE 90402900 T DE90402900 T DE 90402900T DE 69007744 T DE69007744 T DE 69007744T DE 69007744 D1 DE69007744 D1 DE 69007744D1
Authority
DE
Germany
Prior art keywords
leukaemias
human
treatment
interleukin
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE90402900T
Other languages
English (en)
Other versions
DE69007744T2 (de
Inventor
Maud Brandely
Dominique Maraninchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Roussel Uclaf SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussel Uclaf SA filed Critical Roussel Uclaf SA
Application granted granted Critical
Publication of DE69007744D1 publication Critical patent/DE69007744D1/de
Publication of DE69007744T2 publication Critical patent/DE69007744T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69007744T 1989-10-17 1990-10-16 Verwendung von Interleukin 2 zur Behandlung von Leukämien. Expired - Lifetime DE69007744T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8913546A FR2653020B1 (fr) 1989-10-17 1989-10-17 Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour la preparation de compositions pharmaceutiques destinees au traitement des leucemies.

Publications (2)

Publication Number Publication Date
DE69007744D1 true DE69007744D1 (de) 1994-05-05
DE69007744T2 DE69007744T2 (de) 1994-07-28

Family

ID=9386473

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69007744T Expired - Lifetime DE69007744T2 (de) 1989-10-17 1990-10-16 Verwendung von Interleukin 2 zur Behandlung von Leukämien.

Country Status (13)

Country Link
US (1) US5582822A (de)
EP (1) EP0426521B1 (de)
JP (1) JP2961189B2 (de)
KR (1) KR0168420B1 (de)
AT (1) ATE103494T1 (de)
AU (1) AU640173B2 (de)
CA (1) CA2027725A1 (de)
DE (1) DE69007744T2 (de)
DK (1) DK0426521T3 (de)
FR (1) FR2653020B1 (de)
HU (1) HU206048B (de)
OA (1) OA09317A (de)
ZA (1) ZA907648B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2671728B1 (fr) * 1991-01-17 1995-01-20 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour la preparation de compositions pharmaceutiques destinees au traitement des pneumathorax.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5419900A (en) 1993-05-19 1995-05-30 The United States Of America As Represented By The Department Of Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
US5696079A (en) * 1993-05-19 1997-12-09 The United States Of America As Represented By The Department Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
EP2206720A1 (de) 2000-04-12 2010-07-14 Human Genome Sciences, Inc. Albuminfusionsproteine
US6852344B2 (en) * 2000-12-04 2005-02-08 Council Of Scientific And Industrial Research Herbal composition for treating CD33+ acute and chronic myeloid leukemia and a method thereof
GB2372598A (en) * 2001-02-26 2002-08-28 Coppereye Ltd Organising data in a database
EP2261250B1 (de) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin Fusionsproteine
EP1511475B1 (de) * 2002-05-31 2005-10-05 Council of Scientific and Industrial Research Ein kräutermolekül als potentielles anti-leukämisches arzneimittel
US6967034B2 (en) * 2002-05-31 2005-11-22 Council Of Scientific And Industrial Research Herbal-based composition for treating acute and chronic myeloid leukemia
US20070161704A1 (en) * 2002-07-08 2007-07-12 Council Of Scientific And Industrial Research Pharmaceutical composition useful for treating chronic myeloid leukemia
US20040006138A1 (en) 2002-07-08 2004-01-08 Council Of Scientific Pharmaceutical composition useful for treating chronic myeloid leukemia
US20050282892A1 (en) * 2002-07-08 2005-12-22 Santu Bandyopadhyay Pharmaceutical composition useful for treating chronic myeloid leukemia
AU2003266086A1 (en) * 2002-09-16 2004-04-30 Vasogen Ireland Limited Chronic lymphocytic leukemia combination treatment (treated cll cells and cytokine)
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
US7357652B1 (en) * 2006-10-27 2008-04-15 Leviton Manufacturing Company, Inc. Modular wiring system with locking elements
US8206920B2 (en) * 2007-03-26 2012-06-26 Arnold Ganser Diagnostic assay for the specific treatment of acute myeloid leukemia
US10622768B1 (en) 2019-05-10 2020-04-14 Walter Morgan Cowham Methods and systems for a modular plug-in bus wiring system
US10971879B1 (en) 2020-08-12 2021-04-06 Cowham Innovations, LLC. Electrical connection forming tool
CN111821423B (zh) * 2020-08-17 2023-04-11 中南大学湘雅二医院 一种白介素2用于治疗慢性自发性荨麻疹的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8701004D0 (sv) * 1987-03-11 1987-03-11 Astra Ab Method for therapy of leukemias and certain other malignancies
PT89121A (pt) * 1987-12-04 1989-12-29 Du Pont Processo para a preparacao de interleuquina-2 imobilizada e interleuquina-2 contendo uma extensao no terminal-carboxilo com actividade de interleuquina-2 natural
ZA898139B (en) * 1988-11-17 1990-08-29 Hoffmann La Roche Recombinant interleukin-2 hybrid proteins

Also Published As

Publication number Publication date
DE69007744T2 (de) 1994-07-28
ZA907648B (en) 1991-11-27
JPH03193736A (ja) 1991-08-23
HUT55241A (en) 1991-05-28
KR910007541A (ko) 1991-05-30
AU6466790A (en) 1991-04-26
FR2653020B1 (fr) 1993-03-26
EP0426521B1 (de) 1994-03-30
HU206048B (en) 1992-08-28
OA09317A (fr) 1992-09-15
US5582822A (en) 1996-12-10
EP0426521A1 (de) 1991-05-08
DK0426521T3 (da) 1994-05-02
AU640173B2 (en) 1993-08-19
CA2027725A1 (fr) 1991-04-18
JP2961189B2 (ja) 1999-10-12
FR2653020A1 (fr) 1991-04-19
KR0168420B1 (ko) 1999-01-15
ATE103494T1 (de) 1994-04-15
HU906463D0 (en) 1991-04-29

Similar Documents

Publication Publication Date Title
DE69007744D1 (de) Verwendung von Interleukin 2 zur Behandlung von Leukämien.
ATE369383T1 (de) Monoklonale antikörper spezifisch für den zytotoxischen lymphozyten-reifefaktor
HUT38125A (en) Process for preparing lymphokines /cytotoxic factors/ and pharmaceutical compositions containing such active substance
UA39161C2 (uk) Рекомбінантний білок gm-csf для збільшення продукції гранулоцитів і макрофагів у пацієнтів, вектор і кднк, що його кодують
MY101972A (en) Primate interleukin - 4
FI863971A0 (fi) Farmaceutisk komposition anvaendbar vid behandling av leukopenia.
DE68928710D1 (de) T-Zellen-Wachstumsfaktor
EP0231819A3 (en) Pharmaceutical agent for the treatment of myelogenous leukemia
IL102346A0 (en) Cysteine depleted il-6 muteins
DE69031355D1 (de) Verwendung von Human-Beta-Interferon zur Stimulierung der Erythropoiesis
DK0452598T3 (da) Anvendelsen af et polypeptid med humant-inter-leukin-2-aktivitet til fremstilling af farmaceutiske præparater til behandling af primitiv pleuracancer
IE871358L (en) Interferon for carcinoma
DE3869789D1 (de) Behandlung von einigen leukaemien mit einer zusammensetzung von interferon-gamma und interferon-alpha.
ATE145939T1 (de) Mitogen für die glatte muskulatur und dessen kodierende dns
DK0507825T3 (da) Antitumoralt præparat på basis af polypeptider med humant interleukin-2-aktivitet
BG60657B2 (en) Human recombinant interleukin-2 muteins
ZA919682B (en) Use of a polypeptide having human interleukin 2 activity for the preparation of pharmaceutical compositions for the treatment of pneumothorax

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: HOECHST MARION ROUSSEL, PUTEAUX, FR

8327 Change in the person/name/address of the patent owner

Owner name: AVENTIS PHARMA S.A., ANTONY CEDEX, FR

8328 Change in the person/name/address of the agent

Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN

8328 Change in the person/name/address of the agent

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, 80335 MUENC